emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
Search
preserved-heart-failure-treatment-FDA-US-approval
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
emperor-preserved-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
FDA-Fast-Track-chronic-kidney-disease
FDA grants Fast Track designation for the treatment of chronic kidney disease, underscoring urgent need for new treatments for people living with the condition
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction
Animal Health Partnering Interests Cardiometabolic Diseases May 2024 CORP
cardiometabolic_retinal_partner_interests.pdf
CardioMetabolic_diseases.pdf
Cardiometabolic_Diseases.pdf
CardioMetabolic_infographic_Update_2021.pdf
CardioMetabolic_Flyer_BIO_2022.pdf
Partnering_In_CARDIOMETABOLIC_0.pdf
Partnering in Cardiometabolic JAN 2023
Partnering in Cardiometabolic JAN 2023 Corporate
Partnering in Cardiometabolic Diseases MAY 2023 Corp
Partnering in Cardiometabolic Diseases MAY 2024 CORP_0.pdf
CardioMetabolic_infographic_FINAL Dec 18 V2.pdf
cardiometabolic_flyer_bio_2019.pdf
CardioMetabolic_Partnering_Interests_2018-12.pdf
Partnership for new liver disease treatments with Ribo
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
EMPRISE-Study
EMPRISE-Study
emperor-preserved-heart-failure-full-data
Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
Survodutide Phase III study weight loss
Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
Kicking off 2024 with five new R&D partnerships
We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
biopharmaceuticals-in-china
Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.